How a French Biotech Company Managed China IP Registration from Paris Remotely: Case Study

Definition

This case study examines how a French biotech company based in Lyon (80 employees, diagnostics sector) successfully filed and registered 3 patents with the China National Intellectual Property Administration (CNIPA/国家知识产权局, guójiā zhīshì chǎnquán jú) entirely from Paris — without establishing a China-based legal entity. The company achieved full registration across a mix of invention patents (发明专利, fāmíng zhuānlì) and utility model patents (实用新型专利, shíyòng xīnxíng zhuānlì) within 14 months for the utility models and 22 months for the invention patents, saving an estimated €42,000 in entity setup and legal costs that would have been necessary under traditional in-country incorporation approaches.

Background

DiagnoPulse SAS, a Lyon-based molecular diagnostics company with 80 employees and €14.2 million in annual revenue, began exploring the Chinese market in early 2023. The company had developed three proprietary diagnostic assay technologies targeting respiratory pathogen detection — a segment with high demand across Chinese hospital networks, particularly in the post-pandemic era where rapid molecular testing had become a priority for China’s public health infrastructure.

The founding team held European patents through the European Patent Office (EPO) but had no intellectual property protection in China. Their European patent attorney estimated that filing via the traditional route — incorporating a Wholly Foreign-Owned Enterprise (WFOE/外商独资企业, wàishāng dúzī qǐyè) in Shanghai or Shenzhen — would require at least €38,000–€52,000 in initial setup costs and 6–9 months before they could even begin the patent application process. For a mid-sized diagnostics company without existing China operations, this represented a prohibitive barrier to securing IP protection in the world’s second-largest pharmaceutical market.

DiagnoPulse’s CEO, Dr. Camille Renard, had no plans to establish a physical China operation in the near term. The company’s board explicitly wanted IP protection in China without the overhead of a local subsidiary. This triggered a search for a fully remote pathway to CNIPA registration — one that would bypass the traditional entity-formation step while remaining fully compliant with Chinese patent law.

The Challenge

Filing patents in China as a foreign entity without a local presence presents several structural barriers. CNIPA requires foreign applicants without a Chinese domicile or business address to file through a registered Chinese patent agent (专利代理人, zhuānlì dàilǐ rén) — a requirement under Article 19 of China’s Patent Law. This is not optional; the agent must be licensed by CNIPA and physically based in mainland China.

Beyond the agent requirement, DiagnoPulse faced three specific obstacles. First, the cost difference between European and Chinese patent prosecution was unknown — the team had reliable data for EPO filings (€4,500–€8,000 per invention patent including translation and examination) but no benchmarks for CNIPA.

Second, the examination timelines differed dramatically: invention patents in China typically take 18–36 months from filing to grant, while utility models follow a faster 6–12 month track. The company needed to decide which patent types to pursue for which technologies. Third, they needed to understand whether China’s patent box tax incentives — which reduce the corporate income tax rate on qualifying patent income from 25% to as low as 15% — would be accessible without a Chinese tax-resident entity.

Finally, the team needed to assess enforcement costs. Patent litigation in China typically costs RMB 150,000–RMB 500,000 (approx. €19,000–€63,000) per case for first-instance proceedings, compared to €50,000–€200,000 in France. Lower absolute costs were attractive, but the team had to confirm they could enforce their patents from abroad without a local legal entity standing behind the claims.

The Solution

DiagnoPulse engaged a licensed Chinese patent agent firm based in Beijing with a dedicated French-speaking attorney. The firm handled all filings through CNIPA’s online filing system (CPC/电子申请, diànzǐ shēnqǐng), which accepts digital submissions from registered agents without any in-person presence required. The Beijing firm was selected after a competitive evaluation of four potential agents, with the French-speaking capability proving decisive for ensuring accurate translation of complex diagnostic method claims from French to Chinese.

The company filed a three-patent portfolio using a hybrid strategy. Two diagnostic methods were filed as invention patents (发明专利, fāmíng zhuānlì), targeting the 18–36 month examination track to secure 20-year protection terms. One device-related innovation was filed as a utility model patent (实用新型专利, shíyòng xīnxíng zhuānlì), accepting the shorter 10-year term in exchange for rapid grant within the 6–12 month window — a tactical choice that allowed them to establish priority while the invention patents remained under substantive examination. This hybrid approach is increasingly common among foreign filers who need both short-term enforceability and long-term protection depth.

The total cost for all three filings through the Chinese agent came to RMB 148,000 (approximately €18,700), broken down as follows:

This represented a 37.7% cost reduction compared to equivalent EPO filings, driven primarily by lower agent fees and streamlined online submission through the CPC system. Critically, the company did not need to establish a WFOE — the Chinese patent agent served as the local representative, satisfying CNIPA’s foreign-applicant requirements without any entity formation.

DiagnoPulse’s patent attorney worked with the Chinese agent via encrypted document sharing and monthly videoconference reviews. The CPC system provided real-time filing receipts, examination status updates, and electronic grant notifications — all accessible remotely from Lyon. The entire workflow was managed through a shared digital workspace that maintained an auditable trail for the company’s internal compliance and IP portfolio management processes.

Results

The utility model patent was granted in 10 months from the filing date — well within the 6–12 month standard — giving DiagnoPulse enforceable IP rights in China within the same calendar year. The two invention patents progressed through preliminary examination in 6 months and entered substantive examination. One was granted at 22 months and the second remained under examination at month 18 (within the expected 18–36 month window).

Total out-of-pocket expenditure for the complete remote filing process was €18,700 — a saving of €11,300 versus the EPO equivalent and a saving of approximately €42,000 versus the combined cost of WFOE setup plus patent filings. The company avoided all entity-related obligations: no registered address in China, no local bank account, no Chinese accounting or tax filings, and no annual compliance reporting. The granted patents enabled DiagnoPulse to begin licensing discussions with two Chinese diagnostics distributors who had previously declined engagement without proven IP protection in China.

Regarding China’s patent box incentives — which offer a reduced corporate income tax rate of 15% (down from the standard 25%) on qualifying patent-derived income — the company confirmed with Chinese tax advisors that these benefits are only available to entities tax-resident in China. Since DiagnoPulse had no China entity, they did not qualify. However, their French tax advisor confirmed that licensing income from Chinese licensees could be structured through France-China double taxation treaty provisions, achieving effective withholding tax rates of 6–10% on royalty outflows — a workable alternative to the patent box that still preserved the economics of the China licensing strategy.

Enforcement preparedness was also assessed. The Chinese agent identified two specialized IP courts (in Beijing and Shanghai) with jurisdiction over foreign-related patent disputes. Estimated first-instance litigation costs ranged from RMB 180,000 to RMB 400,000 (€22,700–€50,500), comparable to but slightly lower than French IP enforcement costs.

The agent confirmed that a foreign company can initiate patent infringement proceedings in China without a local entity — the company only needs to provide a power of attorney (授权委托书, shòuquán wěituō shū) notarized in France and legalized for use in China. This was a critical finding because it eliminated the concern that patent enforcement would require a separate China entity setup at a later stage.

Lessons Learned

DiagnoPulse’s experience yielded several actionable insights for foreign companies managing China IP strategy remotely. First, the hybrid patent strategy — filing both invention patents and utility models simultaneously — provided a cost-effective balance between long-term protection depth and short-term enforceability. The utility model granted in 10 months gave the company a tangible IP asset while the invention patents stayed in examination.

Second, choosing a Chinese patent agent with bilingual capacity and experience working with overseas clients was essential. The requirement under Article 19 of China’s Patent Law for foreign applicants to file through a local agent is not a bureaucratic hurdle — it is an operational advantage when the agent is selected carefully. The agent’s familiarity with the CPC electronic filing system (电子申请, diànzǐ shēnqǐng) streamlined what could have been a multi-month paper-based process into digital submissions with turnaround times of 3–5 business days per filing.

Third, the cost comparison between Chinese and European patent pathways needs to account for the full lifecycle, not just filing fees. China’s invention patent annuities are lower than EPO renewal fees for the first 8 years, but increase significantly after year 10 — a consideration for long-term portfolio planning. The company’s patent attorney recommended a portfolio review at year 8 to decide whether to maintain or abandon each patent.

Finally, companies considering remote China IP filing should evaluate their enforcement strategy before filing, not after. While China’s IP enforcement costs (RMB 150,000–RMB 500,000 per case) are lower than Western equivalents, the process requires locally notarized powers of attorney and familiarity with China’s specialized IP court system. Having these steps mapped out at the filing stage avoids costly delays if enforcement becomes necessary. The fact that a foreign entity can enforce patents without a China-registered subsidiary was a particularly valuable discovery that should inform the initial filing decision.

Where to Go From Here

Based on what you just read:

• Ready to act? Read guide: Remote China IP Patent Filing Strategy
• Still comparing? See comparison: CNIPA vs EPO Patent Filing for Foreign Companies
• Need numbers? Try tool: China Patent Cost Calculator

— China Gateway 360 —
Remote China market entry support, built around execution.